A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib Tosilate Tablets or Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

This is a randomized, open-label study to evaluate the safety and efficacy of ZG005 in combination with Donafenib or Bevacizumab in patients with advanced hepatocellular carcinoma.

Inclusion Criteria:

• Male or female ≥18 years of age.
• Fully understand the study and voluntarily sign the informed consent form.
• Histologically or cytologically confirmed diagnosis of metastatic or unresectable hepatocellular carcinoma (HCC).
• Life expectancy >= 3 months.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

Exclusion Criteria:

• Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
• Patients were deemed unsuitable for participating in the studyl by the investigator for any reasons.